Latest Articles
-
Pfizer Stock Has Risen 11% In A Month But Will The Gains Continue?
[Updated: 8/3/2021] PFE Stock Update The stock price of Pfizer (NYSE: PFE) has seen an 11% rise over the last twenty-one trading days, and most of the gains have come over the last ten trading days, after the company reported strong Q2 results, ...
-
Pfizer’s Q2 Earnings Snapshot
[Updated: 7/28/2021] Pfizer Earnings Update Pfizer (NYSE: PFE) today reported its Q2 results, which were below our expectations but beat the consensus estimates. The company reported revenues of $19.0 billion, lower than our forecast of $21.7 b...
-
Is Pfizer Stock Set To See Higher Levels Post Q2 Results?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2021 results on Wednesday, July 28. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overall...
-
What’s New With Pfizer’s Covid-19 Vaccine?
Pfizer (NYSE: PFE) has indicated that a third dose of its vaccine may be needed within six to 12 months after full vaccination, as initial immunity wanes and as new and more aggressive variants of the Coronavirus continue to spread. The company...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) and its German partner BioNTech intend to begin clinical trials for an updated version of their Covid-19 vaccine that targets the Delta variant of the Coronavirus. Why? The Delta variant apparently more transmissible ...
-
Is Pfizer Stock A Better Bet Compared To Eli Lilly?
We think that Pfizer (NYSE:PFE) currently is a better pick compared to Eli Lilly & Company (NYSE:LLY) . PFE stock trades at about 5x trailing revenues, compared to around 8x for LLY. Does this gap in Pfizer’s valuation make sense? We...
-
Should You Buy Pfizer For 25% Gains?
[Updated: 5/6/2021] 25% Upside For PFE Stock The stock price of Pfizer (NYSE:PFE) has seen a 7.5% rise over the last ten trading days, and we believe that the stock may continue to trend higher after the company announced solid Q1 results. Pfiz...
-
All Eyes On Covid-19 Vaccine Contribution As Pfizer Reports Its Q1
Pfizer (NYSE: PFE) is scheduled to report its Q1 2021 results on Tuesday, May 4. We expect the company to likely post revenue and earnings above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overall pickup i...
-
Pfizer Covid-19 Vaccine Updates: Booster Shots, E.U. Supplies
Pfizer (NYSE: PFE) and its German partner BioNTech currently produce one of the most sought-after Covid-19 vaccines. Below are some of the recent updates relating to the shot. Firstly, Pfizer CEO Albert Bourla has said that people who receive Co...
-
New Developments For Covid-19 Shot Bode Well For Pfizer Stock
Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 shot has emerged as one of the most sought-after vaccines. Below are some of the recent updates relating to the shot. Pfizer recently indicated that its vaccine was over 91% eff...
-
Will AstraZeneca’s Covid-19 Troubles Help Pfizer Stock?
AstraZeneca’s (LON: AZN) Covid-19 vaccine was seen as key to fighting the pandemic globally, given its low cost and easy distribution, but its roll-out and uptake haven’t exactly been smooth. The shot was recently suspended from use i...
-
Pfizer Covid-19 Vaccine Updates: Will Demand Cool In 2022, Despite Growing Capacity?
Pfizer (NYSE: PFE) and its German partner BioNTech have indicated that they should have the capacity to produce as many as three billion doses of their Covid-19 vaccine in 2022, subject to demand. For perspective, Pfizer intends to produce about ...
-
Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain
Last week, there were two positive developments relating to Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can to...
-
Forecast of the Day: Pfizer’s Immunology Drugs Revenue
FDA has accepted to review Pfizer’s (NYSE: PFE) 20-valent pneumococcal conjugate vaccine for the prevention against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, in adults ages 18 years and older....
-
Buy Pfizer Stock Or JNJ For Vaccine Run?
While Merck looks like the best pick among the three pharma giants, what if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S...
